| HS Code | 400910 |
| Chemical Name | Miconazole |
| Molecular Formula | C18H14Cl4N2O |
| Molecular Weight | 416.13 g/mol |
| Cas Number | 22916-47-8 |
| Physical Appearance | White to almost white crystalline powder |
| Solubility | Practically insoluble in water; soluble in ethanol, methanol, and chloroform |
| Veterinary Grade | Complies with veterinary pharmacopoeial standards |
| Purity Assay | ≥98.5% on dried basis |
| Storage Conditions | Store in well-closed containers, protected from light, at controlled room temperature |
| Compatible Dosage Forms | Tablets, injections, capsules, powders, granules, premix, and solutions |
As an accredited Miconazole Ointment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Miconazole Ointment Veterinary Grade API is supplied as 25 kg net, double polyethylene-lined bags in fiber drums, ready for pharmaceutical formulation. |
| Container Loading (20′ FCL) | 20′ FCL loading of Miconazole Veterinary Grade API, palletized in sealed drums, secured and documented for safe transport. |
| Shipping | Miconazole veterinary grade API ships in sealed, moisture-proof containers to preserve stability. Store at controlled room temperature, protected from light and humidity. Use secure, non-breakable packaging with proper labeling for pharmaceutical raw materials. Deliver via reliable courier with temperature monitoring and traceability to ensure product integrity throughout transit. |
| Storage | Store Miconazole Veterinary Grade API in a well-closed, light-resistant container, in a cool, dry, well-ventilated area. Maintain controlled room temperature (20–25°C, excursions permitted 15–30°C). Protect from moisture, direct sunlight, and incompatible materials. Keep tightly sealed when not in use, away from children and animals. Follow local regulations for handling and disposal. |
| Shelf Life | Shelf life is 24 months when stored as directed in original container, protected from light and moisture. |
Miconazole nitrate is supplied as a micronized powder with a median particle size below 10 µm, which creates severe flow and compaction defects in high-speed rotary presses. The powder exhibits high interparticulate cohesion, low bulk density, and a tendency to stick to steel punches at compression forces above 15 kN. Direct compression is therefore limited to formulations with a drug load below 5% w/w. For veterinary tablets containing 20 mg to 50 mg miconazole nitrate per unit, a wet granulation route is specified. The granulation binder is an aqueous solution of pregelatinized starch at 5% w/w solids, added until granule moisture reaches 18–22% w/w. Granules are dried in a fluid-bed drier at inlet air temperature 60–65°C to a final loss on drying of 1.5–2.5% w/w. Dried granules are passed through a 0.8 mm sieve and blended with lactose monohydrate 30–45% w/w, microcrystalline cellulose 20–35% w/w, crospovidone 2–5% w/w, and magnesium stearate 0.5–1.0% w/w in a bin blender at 15 rpm for 20 min. Compression is performed on a rotary tablet press with 10.0 mm round concave punches, target hardness 60–80 N, friability below 1.0% tested per Ph. Eur. 2.9.7, and disintegration below 15 min in purified water at 37±2°C per Ph. Eur. 2.9.1. Dissolution is evaluated in 900 mL of 0.1 M hydrochloric acid with 0.1% sodium lauryl sulfate using USP apparatus 2 at 50 rpm; a Q value of 75% release at 45 min is commonly applied as an in-house specification for immediate-release veterinary tablets. Film coating is required to mask the bitter taste and protect the API from light. A hydroxypropyl methylcellulose-based film coat is applied to 2–3% weight gain in a perforated pan coater with inlet air temperature 65–70°C. The finished product is packed in aluminum-aluminum blister cavities because miconazole nitrate degrades under light and high humidity. Oral systemic absorption of miconazole after tablet administration is limited and influenced by the fed state; tablets are therefore indicated for accessible mucosal or enteric fungal colonization rather than deep tissue mycosis.
Aqueous injectable preparations of miconazole base are constrained by the extremely low aqueous solubility of the unprotonated form. Aqueous solubility of miconazole nitrate at 25°C is below 1 mg/mL, and injectable solutions require an acidic vehicle containing a nonionic solubilizer. A published formulation approach uses miconazole nitrate at 10 mg/mL in a vehicle of propylene glycol 20–30% v/v, ethanol 10–20% v/v, and polysorbate 80 1–5% w/v, adjusted to pH 3.8–4.5 with hydrochloric acid. The solution is filtered through a 0.22 µm sterilizing-grade polyvinylidene fluoride membrane and filled into 10 mL or 20 mL amber ampoules. Terminal sterilization by autoclaving at 121°C for 15 min may be used if the container closure system withstands the thermal cycle and the pH shift after sterilization is less than 0.3 pH units. Particulate contamination is controlled per Ph. Eur. 2.9.19 and bacterial endotoxins per Ph. Eur. 2.6.14. Dilution with sodium chloride 0.9% w/v injection has not been uniformly validated; dextrose 5% w/v injection is preferred because the higher ionic strength of saline may reduce micellar solubilisation. Published data for this specific veterinary configuration is limited. The diluted infusion must be inspected immediately before administration and discarded if any haze or crystals appear. The parenteral product is intended for treatment of systemic mycoses such as Candida or Aspergillus infections in equine and canine patients under veterinary supervision. Slow intravenous infusion and liver enzyme monitoring are required because miconazole is extensively metabolized by hepatic cytochrome enzymes. The use of miconazole injections in food-producing animals is not authorised in most jurisdictions.
Hard gelatin capsules containing 10 mg or 20 mg miconazole nitrate present a low-dose mixing challenge because the micronized API has a high surface area and tends to form cohesive agglomerates. Segregation is controlled by preparing a 1:5 w/w pre-blend with lactose monohydrate passed through a 0.5 mm screen. The pre-blend is then diluted stepwise into a final blend composed of lactose monohydrate 60–80% w/w, pregelatinized starch 10–20% w/w, colloidal silicon dioxide 0.2–0.5% w/w, and magnesium stearate 0.25–0.5% w/w. Blending is performed in a bin blender at 12–15 rpm for 20–30 min after each addition; the final blend is sampled at 10 locations and content uniformity is required to meet Ph. Eur. 2.9.40 acceptance value ≤15. Production records show that blend uniformity failures are more frequent when room humidity exceeds 40% RH because micronized miconazole nitrate picks up moisture and forms agglomerates on blender walls. Capsules are filled on an MG2 or Zanasi dosator machine with size 3 or 4 shells at 60–80% relative humidity in the filling room to maintain shell brittleness. Average fill weight is controlled to ±3% and individual capsule weight variation per Ph. Eur. 2.9.5. Dissolution testing uses 900 mL of 0.1 M hydrochloric acid with 0.1% sodium lauryl sulfate at 37±0.5°C with USP apparatus 1 at 100 rpm. The finished capsules are packaged in HDPE bottles with desiccant. The clinical terminal product is used for protracted oral antifungal treatment in companion animals with gastrointestinal candidiasis or malassezia overgrowth where topical therapy is insufficient. The product is not interchangeable with systemic azoles in cases of deep organ infection because miconazole oral absorption is limited.
Topical dusting powders containing 2.0% w/w miconazole nitrate are manufactured by low-shear blending to avoid fracture of the micronized drug particles. The formulation combines zinc oxide 10–20% w/w, starch 20–30% w/w, and talc q.s. to 100% w/w. The API is first passed through a 0.5 mm stainless steel sieve together with an equal portion of starch to deagglomerate. The remaining components are charged to a ribbon blender and mixed at 10–15 rpm for 30 min. Batch uniformity is assessed by sampling 10 representative points and assaying miconazole nitrate by high-performance liquid chromatography with a relative standard deviation of ≤2.0%. Microbial quality is controlled per Ph. Eur. 5.1.4 category 2 for topical products; selected batches are screened for Candida albicans and Aspergillus brasiliensis per Ph. Eur. 5.1.3. The finished powder is filled into HDPE sifter-top containers. Terminal use is limited to non-occluded application on interdigital spaces, axillae, and skin folds in dogs and cats with dermatophytosis or Malassezia dermatitis. Inhalation risk requires a particle size distribution where the fraction below 10 µm is minimised; this is achieved by controlling the fines content of talc and avoiding jet-milled API. The powder should not be applied to open wounds or mucous membranes.
Fluid-bed granulation is preferred when the final granules must exhibit a friable and highly porous structure for rapid reconstitution into an oral suspension. Miconazole nitrate is granulated with a binder solution of hypromellose 3–5% w/w and purified water. The dry mix comprises miconazole nitrate 5% w/w, lactose monohydrate 40–60% w/w, microcrystalline cellulose 20–30% w/w, and croscarmellose sodium 2–4% w/w. Processing in a top-spray fluid-bed granulator uses inlet air temperature 55–65°C, spray rate 8–12 g/min, atomization pressure 1.0–1.5 bar, and bed temperature 30–35°C. Granulation end point is controlled by loss on drying rather than impeller torque because hydrophobic miconazole nitrate surfaces delay water distribution and produce misleading power consumption readings. Dried granules are sieved through 0.8 mm and blended with talc 1–2% w/w. Flowability is evaluated by Ph. Eur. 2.9.36; an angle of repose below 35° and a compressibility index below 25% are considered acceptable for automatic sachet filling. Bulk density is typically controlled between 0.45 g/mL and 0.60 g/mL to maintain filling accuracy. The granules are filled into aluminium sachets at 1.0 g or 2.0 g net weight for reconstitution with purified water to 10 mL or 20 mL. The reconstituted suspension is a finished oral dosage form for use in dogs, cats, and foals; it must be shaken vigorously immediately before each dose because miconazole nitrate particles settle rapidly. Preservative efficacy of the reconstituted vehicle is tested per Ph. Eur. 5.1.3 for oral liquids. The product is not intended for parenteral use.
A dry premix containing 10% w/w miconazole nitrate on lactose monohydrate is used as an intermediate for extemporaneous oral suspensions and pastes. The premix is manufactured in a double-cone blender with an intensifier bar; silicon dioxide 0.5–1.0% w/w is included as a flow aid. The API is first screened with an equal part of lactose through a 0.5 mm sieve. Blending proceeds at 15 rpm for 30 min with the intensifier bar activated for the final 5 min at 1500 rpm. Content uniformity is confirmed by 10 sampling points; acceptance is consistent with Ph. Eur. 2.9.40. Water activity is monitored and maintained below 0.60 to prevent hydrolysis of miconazole nitrate in the dry state. The premix is packed in double polyethylene bags inside fibre drums, with desiccant. At the point of use, the veterinary pharmacist reconstitutes the premix into a suspension vehicle containing carboxymethylcellulose sodium 1–2% w/v, benzyl alcohol 0.5% w/v, and sorbitol 20–30% w/v. The final suspension is assigned a beyond-use date not exceeding 14 days under refrigeration at 2–8°C. Carryover in non-dedicated equipment is a practical concern; cleaning validation swab limits for miconazole nitrate are set conservatively because miconazole is a potent imidazole antifungal. The premix is not intended for food-producing animal feed; no maximum residue limit has been harmonised for such use in major veterinary medicine jurisdictions.
Aqueous topical and otic solutions of miconazole nitrate require an acidic environment to maintain solubility of the weakly basic drug. Solubility increases as pH decreases, but pH below 3.5 may cause stinging and epithelial irritation in inflamed ear canals. A typical 1% w/v miconazole nitrate solution is formulated with propylene glycol 10–30% w/v, ethanol 10–20% w/v, polysorbate 80 1–5% w/v, and benzalkonium chloride 0.02% w/v as preservative. The API is dissolved in the co-solvent phase at 40–50°C under stirring; purified water is then added gradually to avoid local precipitation. The finished solution is cooled, filtered through a 0.45 µm membrane, and filled into amber HDPE dropper bottles. pH is controlled per Ph. Eur. 2.2.3 within 3.8–4.5; osmolality is measured per Ph. Eur. 2.2.35 and adjusted with sodium chloride if needed. Preservative efficacy is validated per Ph. Eur. 5.1.3 using Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. The terminal product is indicated for canine and feline otitis externa associated with Malassezia pachydermatis and for localized dermatophytosis. The solution must not be used in animals with a perforated tympanic membrane. Anionic surfactants and strong oxidizing agents are incompatible with benzalkonium chloride and should not be used as cleaning agents on production lines. The product should be stored below 25°C and protected from light; a slight yellow tint may develop after prolonged storage without exceeding degradation limits.
Semi-solid veterinary ointments containing 2.0% w/w miconazole nitrate are manufactured by dispersing the micronized API into a molten lipophilic base at 70–75°C. A typical anhydrous base consists of white soft paraffin 40–60% w/w, liquid paraffin 10–20% w/w, and lanolin alcohol 5–10% w/w. The API is passed through a 0.25 mm screen and levigated with a portion of liquid paraffin before incorporation into the molten base. Mixing continues under low-shear planetary agitation at 20–30 rpm while cooling to 40°C; the product is then filled into collapsible aluminium tubes or polypropylene jars. Homogeneity is verified by assay at the top, middle, and bottom of the holding tank; the relative standard deviation must be ≤2.0%. Microbial quality for cutaneous products is controlled per Ph. Eur. 5.1.4. The finished ointment is used for localized dermatophytosis, Malassezia dermatitis, and mixed bacterial-fungal skin infections in dogs, cats, and horses. The anhydrous base provides an occlusive environment that enhances drug retention in the stratum corneum. Miconazole nitrate is incompatible with strong oxidising agents and must not be milled with heat-generating equipment during dispersion. Published data on in vivo release from this specific veterinary configuration is limited; diffusion testing through synthetic membranes may be performed as a batch-to-batch control using Franz cells at 32°C with a receptor medium containing 30% ethanol in phosphate-buffered saline at pH 4.0.
Competitive Miconazole Ointment Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Designated chemically as 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole nitrate, CAS 22832-87-7, the veterinary-grade miconazole nitrate API is a crystalline imidazole antifungal released against the current Ph. Eur. and USP monographs with an assay acceptance range of 99.0–101.0 % w/w on the dried basis. The nitrate salt has a molecular weight of 479.14 g/mol and the empirical formula C18H14Cl4N2O·HNO3. The compound is practically insoluble in water, sparingly soluble in ethanol, and freely soluble in dimethylformamide; aqueous solubility is pH-dependent but remains below the threshold for simple solution-based injectables without a solubility-enhancement strategy. Antifungal activity results from inhibition of lanosterol 14α-demethylase (CYP51), which blocks ergosterol biosynthesis in Malassezia pachydermatis, Candida albicans, Trichophyton spp., Microsporum spp., and certain Aspergillus spp. The product therefore functions as a broad-spectrum imidazole for topical, oral, and feed-directed veterinary formulations, although the specific dosage form must be matched to particle size, carrier composition, and manufacturing sequence.
Two process-controlled grades are supplied under the same veterinary monograph: a standard milled powder with a laser-diffraction D90 ≤ 150 µm for dry granulation, premix, capsule, and powder blends, and a micronized powder with D90 ≤ 25 µm for anhydrous ointments, oil-in-water creams, and suspension-based dosage forms. The micronized grade reduces particle grittiness in semisolid preparations and decreases sedimentation velocity in liquid suspensions, while the standard grade limits dust formation during feed-mill loading and provides adequate flow on rotary press feed frames. This dual-grade design differs from a commodity human topical miconazole nitrate supply, which is commonly released only as a coarse crystalline powder without a controlled particle-size distribution for veterinary feed homogenisation. Micronization is carried out by jet milling with nitrogen at 6–8 bar grinding pressure and classifier speed selected to hold D90 ≤ 25 µm; milled product is sieved through a 150 µm safety screen.
The veterinary-grade designation does not signal a different molecular entity but indicates that release and packaging are managed to support non-sterile veterinary dosage forms, feed premixes, and topical applications under current VICH GMP provisions. Compared with miconazole base, the nitrate salt provides improved handling, a defined melting range, and compendial identity, but it retains the base’s poor aqueous solubility; formulations that require rapid dissolution must use micronization, inclusion complexation, or co-solvent systems. In comparison with ketoconazole, miconazole nitrate is selected for topical and oral non-systemic uses in companion animals because systemic absorption after topical application is generally low; ketoconazole is more frequently reserved for systemic or systemic-adjacent indications. Compared with clotrimazole, miconazole nitrate demonstrates a similar imidazole mechanism but different hydrophobic ion-pairing behaviour in anhydrous ointment matrices; the selection between these actives is therefore dictated by the target species, the vehicle pH, and the release profile desired in the first 6 h of contact time. Miconazole nitrate is also distinct from nystatin, which is a polyene rather than an azole; nystatin is limited to gastrointestinal and topical use, while miconazole can cross mucosae in small quantities and therefore has a broader but more formulation-dependent safety profile. In combined veterinary dermatological preparations, miconazole nitrate is frequently co-formulated with chlorhexidine gluconate or corticosteroids; however, the nitrate salt may interact with cationic surfactants at high concentration if the vehicle pH is above 6.5, requiring compatibility studies by HPLC and zeta potential measurement. Miconazole nitrate is not compatible with strong oxidising agents, and the imidazole ring is susceptible to oxidative discolouration; the product is therefore packed in nitrogen-flushed polyethylene-aluminium foil liners to limit headspace oxygen below 2 % v/v during transit.
The following release matrix applies to both particle-size grades. Values are tested on each batch by the corresponding Ph. Eur./USP method; where the method is not a monograph requirement, the technical specification is agreed with the contract manufacturer and reported on the certificate of analysis.
| Parameter | Limit | Reference/Test Method |
|---|---|---|
| Appearance | White or almost white crystalline powder | Ph. Eur. visual examination |
| Identification | Infrared spectrum concordant with reference; HPLC retention time concordant | Ph. Eur. 2.2.24; stability-indicating HPLC |
| Assay, dried basis | 99.0–101.0 % w/w as C18H14Cl4N2O·HNO3 | HPLC against USP/Ph. Eur. reference standard |
| Loss on drying | ≤ 0.5 % | Ph. Eur. 2.2.32 |
| Sulfated ash | ≤ 0.1 % | Ph. Eur. 2.4.14 |
| Related substances | Individual impurity ≤ 0.25 %; total impurities ≤ 0.5 % | Stability-indicating HPLC; forced degradation under 0.1 M HCl, 0.1 M NaOH, and 3 % H₂O₂ |
| Residual solvents | ICH Q3C Option 2 limits | Headspace gas chromatography; ethanol is monitored as the principal recrystallisation solvent |
| Elemental impurities | ICH Q3D Category 2 limits | ICP-MS after closed-vessel acid digestion |
| Particle size, micronized grade | D90 ≤ 25 µm | ISO 13320:2020 |
| Particle size, standard grade | D90 ≤ 150 µm | ISO 13320:2020 |
| Bacterial endotoxins, injectable grade | < 0.50 EU/mg when ordered as injectable grade; otherwise not routine | Ph. Eur. 2.6.14 |
| Microbial enumeration | Not routine for dry API; available by agreement for non-sterile oral/topical applications | Ph. Eur. 2.6.12/2.6.13 |
Residual solvent control follows ICH Q3C Option 2 limits using headspace gas chromatography; because the final step recrystallises the nitrate from an ethanol/water mixture, the principal solvent to be monitored is ethanol. Elemental impurity release follows ICH Q3D Category 2 limits with ICP-MS after closed-vessel acid digestion. The assay method is stability-indicating and resolves the 2,4-dichlorophenyl hydrolysis fragment from the parent peak; forced degradation studies conducted under 0.1 M HCl, 0.1 M NaOH, and 3 % H₂O₂ demonstrate that the acid and base degradation products are separated with a resolution factor above 2.0 in production QC. These controls differentiate a documented veterinary API supply from loosely specified compounding-grade miconazole nitrate, which may lack particle-size certification and impurity traceability.
For tablet manufacturing, direct compression is generally unsuitable for miconazole nitrate because the crystalline powder exhibits low compactability, high interparticulate friction, and sticking on hardened steel tooling. A robust process uses high-shear wet granulation with povidone K-30 or pregelatinised maize starch as binder at 3–5 % w/w dry basis, purified water acidified to pH 4.5–5.5 with citric acid. Granulation endpoints are controlled by impeller power draw and chopper speed rather than fixed time; typical pilot-scale parameters on a 25 L vertical granulator are impeller speed 150–250 min−1 and chopper speed 1,500–2,500 min−1. Drying is performed in a fluid-bed dryer with inlet air at 50–55 °C until granule moisture reaches 1.5–2.0 % w/w. The dried granules are screened through an 800 µm sieve, lubricated with 0.5 % w/w magnesium stearate in a V-blender for 3 min, and compressed on a rotary tablet press. Tablet hardness is set to achieve disintegration below 15 min in 0.1 M HCl using USP <701>, and content uniformity is verified by USP <905> or Ph. Eur. 2.9.40. Where dissolution is specified, the medium 0.1 M hydrochloric acid with 0.5 % w/v sodium lauryl sulfate is often evaluated as a discriminating medium; published data for this specific veterinary tablet configuration is limited and should be generated on a case-by-case basis.
Capsule filling with miconazole nitrate requires attention to flow and bulk density. The API is blended with lactose monohydrate and microcrystalline cellulose in a bin blender at 60–70 % fill, then passed through a 0.8 mm sieve to break soft agglomerates. Encapsulation on a dosator or tamping-pin machine is performed with fill weight control at ± 5 % and periodic composite assay; the hard gelatin shell may be stored at 35–45 % RH to prevent brittleness. If capsules are opened and sprinkled on feed, the particle-size distribution is shifted toward granules to reduce oral dust aspiration, but the powder grade may also be used when an appropriate dust-suppression protocol is in place.
In medicated premix, the miconazole nitrate content may be reduced to 1–10 kg per tonne of final feed; therefore, simple direct blending is insufficient. The process is executed with a horizontal ribbon mixer or double-shaft paddle mixer at 60–70 % of working volume using geometric dilution. The first premix is prepared at 1:10 with lactose monohydrate or precipitated calcium carbonate; the second at 1:10 with the feed carrier to yield a 1:100 premix; the final blend is carried out at the feed mill. Mixing time is established by homogeneity studies in the actual equipment, with sampling at 10 points distributed across the mixer according to Ph. Eur. 2.9.40 or USP <905> principles; a relative standard deviation of ≤ 5.0 % is a typical release target. If the API is micronized, electrostatic adhesion to stainless steel surfaces increases during low-humidity winter production; an anti-static additive or humidity-controlled environment set to 40–55 % RH is used. When the standard milled grade is selected, dust generation is reduced but segregation on vibratory discharge can occur; a post-mix particle-size check by ISO 13320:2020 or sieve analysis is performed to verify that the carrier and API fractions have not separated. In feed-mill operations, the premix is added to the final feed in a single-stage or two-stage mixer, and retained samples are tested for content uniformity to close out the batch record.
Miconazole nitrate is stable in dry, cool storage, but aqueous granulation introduces hydrolysis and oxidation risk that is visible as increases in the unknown related substance region on thin-layer chromatography. Granulation fluids are buffered to pH 4.5–5.0 because the imidazole ring and the ether bridge are most stable in mildly acidic conditions; above pH 8.0, degradation accelerates significantly. The fluid-bed dryer inlet air is maintained below 60 °C; excursions above 70 °C for longer than 30 min are associated with off-white discolouration and elevated total related substances in production-scale campaigns. Residual moisture in granules is kept between 1.0 % w/w and 2.0 % w/w; lower moisture increases tablet capping, while higher moisture increases sticking and impurity formation during storage at 40 °C/75 % RH in open-bag stability studies. Stability samples are tested according to ICH Q1A(R2) at 25 °C/60 % RH and 40 °C/75 % RH for at least 6 months to confirm that the chosen granulation route does not create a new degradation pathway. Strong acidic or alkaline excipients should be avoided; anhydrous lactose and microcrystalline cellulose are compatible, but wet granulation with povidone requires acidification as described. The API is incompatible with chlorinated cleaning agents that may leave peroxide residues on contact surfaces.
For anhydrous ointment and cream manufacture, the micronized grade is levigated with approximately 10 % of the oil phase, typically mineral oil or caprylic/capric triglyceride, before being added to the molten ointment base at 45–50 °C. A rotor-stator mixer operating at 3,000–5,000 min−1 disperses agglomerates; vacuum deaeration at −0.8 bar follows to remove air bubbles that would otherwise appear as undispersed specks. In water-washable emulsion ointments, miconazole nitrate is dispersed in the oil phase before phase combination; this prevents migration of particulate drug to the aqueous interface and improves content uniformity. The dispersed phase is then homogenised to a mean particle size D50 ≤ 10 µm and checked by light microscopy or laser diffraction. Solutions are more demanding: miconazole nitrate dissolves sufficiently in ethanol, propylene glycol, or polyethylene glycol 400, but aqueous dilution beyond 20 % v/v can cause precipitation during cold storage at 5 °C. Oral liquid suspensions intended for dogs or cats are commonly compounded as 2 % w/v suspensions. The micronized API is dispersed in a vehicle containing sodium carboxymethylcellulose 0.5 % w/v, polysorbate 80 at 0.2 % w/v, and citrate buffer pH 4.5; homogenisation at 10,000 min−1 for 5 min produces a suspension that passes re-dispersibility testing after 24 h without excessive foam. These are process capability targets, not regulatory specifications.
Injectable use is the most restrictive formulation path. Because miconazole nitrate is practically insoluble in water, simple aqueous injection is not feasible at therapeutic concentrations. Solubility in 40 % w/v hydroxypropyl-β-cyclodextrin approaches a few milligrams per millilitre, but published data for this specific veterinary configuration is limited; feasibility batches must therefore be developed with a phase-solubility study at 25 °C and 37 °C. If a suspension is required, the micronized grade is dispersed in polysorbate 80 and citrate-buffered vehicle at pH 4.5, then homogenised at 800–1,200 bar in a high-pressure homogeniser until mean particle size is below 2 µm. Terminal steam sterilisation at 121 °C for 15 min may increase related substances; aseptic filtration of a suspension is not possible, so the product must be sterile-filtered as a solution and then aseptically mixed with sterile excipients or terminally sterilised with a validated cycle. The API is not, by default, sterile or endotoxin-controlled for parenteral use; a dedicated injectable grade with bacterial endotoxin below 0.50 EU/mg and sterility tested per Ph. Eur. 2.6.1 is required if this route is selected.
